265 related articles for article (PubMed ID: 38046909)
21. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
22. 2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction.
Li YH; Wang CC; Hung CL; Wu YW; Hsu CH; Tsou YL; Wang CH; Wu CK; Lin PL; Chang HY; Sung SH; Chen ZW; Juang JJ; Wang TD; Chen WJ
Acta Cardiol Sin; 2024 Mar; 40(2):148-171. PubMed ID: 38532817
[TBL] [Abstract][Full Text] [Related]
23. Anemia has an impact on prognosis in heart failure with preserved ejection fraction with mild chronic kidney disease.
Okuno K; Naito Y; Asakura M; Sugahara M; Horimatsu T; Yasumura S; Tahara S; Nagai T; Saito Y; Yoshikawa T; Masuyama T; Ishihara M; Anzai T
Int J Cardiol Heart Vasc; 2021 Jun; 34():100796. PubMed ID: 34095449
[TBL] [Abstract][Full Text] [Related]
24. Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets.
van de Wouw J; Broekhuizen M; Sorop O; Joles JA; Verhaar MC; Duncker DJ; Danser AHJ; Merkus D
Front Physiol; 2019; 10():1108. PubMed ID: 31551803
[TBL] [Abstract][Full Text] [Related]
25. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Packer M; Kitzman DW
JACC Heart Fail; 2018 Aug; 6(8):633-639. PubMed ID: 29525327
[TBL] [Abstract][Full Text] [Related]
26. Managing heart failure with preserved ejection fraction.
Davidson A; Raviendran N; Murali CN; Myint PK
Ann Transl Med; 2020 Mar; 8(6):395. PubMed ID: 32355839
[TBL] [Abstract][Full Text] [Related]
27. Targeting epicardial adipose tissue: A potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus.
Shi YJ; Dong GJ; Guo M
World J Diabetes; 2023 Jun; 14(6):724-740. PubMed ID: 37383601
[TBL] [Abstract][Full Text] [Related]
28. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
29. Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Hegyi B; Mira Hernandez J; Ko CY; Hong J; Shen EY; Spencer ER; Smoliarchuk D; Navedo MF; Bers DM; Bossuyt J
J Am Heart Assoc; 2022 Dec; 11(23):e027164. PubMed ID: 36416174
[TBL] [Abstract][Full Text] [Related]
30. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
Löfman I; Szummer K; Dahlström U; Jernberg T; Lund LH
Eur J Heart Fail; 2017 Dec; 19(12):1606-1614. PubMed ID: 28371075
[TBL] [Abstract][Full Text] [Related]
31. Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder?
Shah KS; Fang JC
Curr Hypertens Rep; 2019 Oct; 21(11):86. PubMed ID: 31599363
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Metabolic-Inflammatory Circuit in Heart Failure With Preserved Ejection Fraction.
Yap EP; Kp MMJ; Ramachandra CJ
Curr Heart Fail Rep; 2022 Jun; 19(3):63-74. PubMed ID: 35403986
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a robust mouse model of heart failure with preserved ejection fraction.
Matsiukevich D; Kovacs A; Li T; Kokkonen-Simon K; Matkovich SJ; Oladipupo SS; Ornitz DM
Am J Physiol Heart Circ Physiol; 2023 Aug; 325(2):H203-H231. PubMed ID: 37204871
[TBL] [Abstract][Full Text] [Related]
34. Heart Failure With Preserved Ejection Fraction: An Evolving Understanding.
Tah S; Valderrama M; Afzal M; Iqbal J; Farooq A; Lak MA; Gostomczyk K; Jami E; Kumar M; Sundaram A; Sharifa M; Arain M
Cureus; 2023 Sep; 15(9):e46152. PubMed ID: 37900404
[TBL] [Abstract][Full Text] [Related]
35. Obesity-related heart failure with preserved ejection fraction: new treatment strategies.
Chrysant SG; Chrysant GS
Hosp Pract (1995); 2019 Apr; 47(2):67-72. PubMed ID: 30712418
[TBL] [Abstract][Full Text] [Related]
36. [Diastolic heart failure: 20 years later. Сurrent issues of pathoge-nesis, diagnosis and treatment of heart failure with preserved LVEF].
Ageev FT; Ovchinnikov AG
Kardiologiia; 2023 Mar; 63(3):3-12. PubMed ID: 37061855
[TBL] [Abstract][Full Text] [Related]
37. Patient selection for mineralocorticoid receptor antagonists in heart failure with mildly reduced or preserved ejection fraction.
Vardeny O; Houle H
Pharmacotherapy; 2023 Jun; 43(6):563-569. PubMed ID: 37021777
[TBL] [Abstract][Full Text] [Related]
38. Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies.
Abdin A; Böhm M; Shahim B; Karlström P; Kulenthiran S; Skouri H; Lund LH
Int J Cardiol; 2024 Jun; ():132304. PubMed ID: 38944348
[TBL] [Abstract][Full Text] [Related]
39. Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review.
Mares A; Rodriguez T; Deoker A; Lehker A; Mukherjee D
Curr Vasc Pharmacol; 2022; 20(1):46-51. PubMed ID: 34303331
[TBL] [Abstract][Full Text] [Related]
40. Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
Pabel S; Hamdani N; Singh J; Sossalla S
Front Physiol; 2021; 12():752370. PubMed ID: 34803735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
